Clinical Trials Logo

Graft Function/Survival clinical trials

View clinical trials related to Graft Function/Survival.

Filter by:
  • None
  • Page 1

NCT ID: NCT00307125 Completed - Kidney Transplant Clinical Trials

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

Start date: March 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether treatment with rituximab (anti-CD20, Rituxan®, MabThera®) in individuals who develop new anti-HLA antibodies after renal (kidney) transplant will promote longer-term survival of the transplanted kidney.The pilot study compares the use of rituximab (Rituxan®) + site-specific standard immunosuppression to placebo + site-specific standard immunosuppression in the treatment of circulating anti-HLA antibodies in subjects who develop de novo anti-HLA antibodies between 3-36 months after transplant.